Zydus receives WHO acceptability for ZyVac TCV, eligible for UN agency purchases
ZyVac TCV, developed by Zydus Lifesciences, gains prequalification from WHO for global typhoid immunisation programmes
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Zydus Lifesciences
Zydus gains final USFDA approval for Fludrocortisone Acetate Tablets USP, 0.1 mg
Fludrocortisone acetate tablets had annual sales of $ 19.9 mn in the United States (IQVIA MAT July 2024)
Zydus, ICMR initiate Phase 2 clinical trial of Desidustat in patients with Sickle Cell Disease
The trial will also evaluate Key Secondary Endpoints including Mean change in haemoglobin, the proportion of patients requiring…
Zydus gains final USFDA approval for Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and…
The tablets are indicated for the acute and maintenance treatment of schizophrenia
Zydus gains final USFDA approval for Amantadine extended-release capsules 68.5 mg and tentative…
Eligible for 180 days of generic drug exclusivity for Amantadine extended release capsules, 68.5 mg
Zydus receives USFDA warning letter for Jarod facility
Earlier, on July 18, the facility received an OAI status
Zydus Lifesciences receives U.S. FDA approval for Scopolamine Transdermal System
Zydus gains final approval to market Scopolamine Transdermal System, marking its fifth ANDA approval in the transdermal portfolio…
Zydus gains final USFDA approval for Valbenazine Capsules
Valbenazine Capsules had annual sales of $ 1,993.6 million in the United States (IQVIA MAT June 2024)
Zydus receives approval from COFEPRIS of Mexico to market Mamitra
The Mexican regulatory authority has granted marketing approval for a Trastuzumab biosimilar to treat various cancers
Zydus receives final US FDA nod for Valsartan Tablets
Valsartan tablets had annual sales of $149.5 mn in the United States (IQVIA MAT May 2024)